The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Breast Cancer Liquid Biopsy Market Evolve From 2026 To 2030?
The breast cancer liquid biopsy market size has seen rapid growth over recent years. It is projected to expand from $0.89 billion in 2025 to $1.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. This historical growth can be attributed to factors such as the rising incidence of breast cancer, the inherent limitations of tissue biopsy, breakthroughs in oncology diagnostics, increased public awareness regarding screening, and the broader expansion of laboratory testing services.
The breast cancer liquid biopsy market size is set to experience significant growth in the upcoming years. It is projected to expand to $1.75 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. This anticipated growth is primarily driven by the increasing adoption of precision oncology, advancements in AI-based mutation analysis, personalized treatment planning, an uptick in cfDNA testing, and the expansion of decentralized cancer diagnostics. Notable trends expected during this period involve multi-biomarker blood-based testing, non-invasive methods for cancer monitoring, tracking treatment response, early recurrence detection, and personalized oncology diagnostics.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp
What Drivers Are Influencing The Breast Cancer Liquid Biopsy Market?
The rising incidence of breast cancer is anticipated to fuel the expansion of the breast cancer liquid biopsy market. Breast cancer originates in the breast cells, commonly in the lobules (milk-producing glands) or ducts (passages transporting milk to the nipple). This surge in cases is attributed to various factors such as genetic predisposition, hormonal imbalances, an aging demographic, altered lifestyles, obesity, alcohol intake, insufficient physical activity, radiation exposure, and environmental contaminants. In treatment, a breast cancer liquid biopsy serves to identify circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream, enabling real-time disease monitoring. This method assists in evaluating treatment effectiveness, identifying resistance to therapies, and pinpointing genetic mutations crucial for targeted treatments. For example, the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, projects new breast cancer cases to reach 319,750 in 2025, an increase from 313,510 cases in 2024. Consequently, the expanding number of breast cancer cases is propelling the growth of the breast cancer liquid biopsy market.
Which Segment Areas Are Covered In The Breast Cancer Liquid Biopsy Market Analysis?
The breast cancer liquid biopsy market covered in this report is segmented –
1) By Product: Consumables, Kits
2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
3) By Application: Early Detection Or Screening, Diagnosis, Other Applications
4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories
Subsegments:
1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits
What Key Developments And Trends Are Impacting The Breast Cancer Liquid Biopsy Market?
Leading companies active in the breast cancer liquid biopsy market are concentrating on creating innovative products, such as companion diagnostics, to enable personalized treatment methods by identifying patients who respond well to specific therapies. Companion diagnostics utilize liquid biopsy technologies to detect biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that signal treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test, which functions as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to employ the test for comprehensive genomic profiling, thereby pinpointing patients who could benefit from the targeted therapy. This achievement represents Guardant Health’s initial U.S. Food and Drug Administration (FDA) approval in the breast cancer field and enhances its role in precision oncology.
Which Global Companies Are Actively Competing In The Breast Cancer Liquid Biopsy Market?
Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc
Read the full breast cancer liquid biopsy market report here:
https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report
Which Regions Are Expected To Experience Rapid Expansion In The Breast Cancer Liquid Biopsy Market?
North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Breast Cancer Liquid Biopsy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp
Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2026, By The Business Research Company
Liquid Biopsy Market Report 2026
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report
Breast Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report
Biopsy Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model